NCT04862780 2025-02-10
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
Blueprint Medicines Corporation
Georgetown University
ETOP IBCSG Partners Foundation
Blueprint Medicines Corporation
First Affiliated Hospital of Zhejiang University
The Netherlands Cancer Institute
Daiichi Sankyo